ARVN:NASDAQ, Arvinas, Inc.

Why ARVN stock fell on November 5

Arvinas, Inc. fell 11.7% on Thursday, November 5, 2026, on 1,261,100 shares. Headlines around the move:

Nov 4: Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting
Nov 4: Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
Nov 4: What Arvinas Bears Saw Before The Fall

ARVN stock overview

Arvinas, Inc. (ARVN:NASDAQ) closed at $6.41 on November 6, 2026, down 2.14% on the day. The stock trades 55.8% below its 52-week high of $14.51 and 0.5% above its 52-week low of $6.38. Over the past year, it lost 39.7%. Arvinas, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $6.41
Day change: -2.14%
Volume: 1,212,725
Average volume: 789,150
Market cap: 419M+
52-week range: $6.38 – $14.51
50-day average: $7.92
200-day average: $9.58

Price action over the past year

In 252 trading sessions since November 6, 2025, ARVN closed higher on 110 days (44%). Its best day was November 18, 2025 (+17.66%) and its worst was November 5, 2026 (-11.73%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

Nov 6, 2026: Down 28.7% over 90 days, from $8.99 (Dips & Crashes scanner)
Nov 6, 2026: Hit a new 52-Week Low of $6.41 (New Highs/Lows scanner)
Nov 4, 2026: News catalyst: Biotech (News Catalysts scanner)

ARVN news

About Arvinas, Inc.

Arvinas Inc, formerly Arvinas Holding Co LLC is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary PROTAC protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.

Similar stocks

Find more stocks like ARVN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.